Ortho Clinical Diagnostics is committed to constantly evaluating our assay portfolio to bring you a broad disease state menu that meets your testing needs and helps doctors and patients know more so treatment decisions can be made sooner.
Our menu covers 90% of the menu needs and 99% of the testing volume for typical labs with:
+ Over 120 available assays
+ 10 user-defined chemistry channels
+ Wide accessible menu on-board at all times
+ Standardized reagents and results across all VITROS® platforms
World-class assays for quality results
VITROS® DAT Assays
Excellent correlation to EMIT® and greater precision increase confidence in patient results. Allows consolidation with routine chemistry.
VITROS® Troponin I ES Assay
Improved sensitivity delivers reliable information for patients with acute coronary syndrome. Meets ACC/ESC guideline for acceptable imprecision in a high sensitivity assay (10% CV at 99th percentile).
VITROS® NT-proBNP Assay
Provides confidence to physicians for the differential diagnosis of heart failure, improving patient care. Enables consolidated cardiac testing on one fully random-access system. Adopted in ESC/ACC/AHA practice guidelines.1,2
VITROS® d%A1C Assay
High-quality results with traceability to the NGSP and IFCC Standards. No manual pre-treatment means fewer potential errors.
VITROS® TSH 3rd Generation Assay
Third generation sensitivity means this assay can be used as a front-line screen that enables cost-effective algorithmic testing stratetgies.3,4,5,6 Smaller sample volume minimizes costs and operator intervention.
VITROS® Free T4 Assay
Correlates with Equilibrium Dialysis (ED), considered the “Gold Standard” for free hormone analysis.7,8 Not impacted by serum protein concentrations allowing for better differentiation of non-thyroidal illness.
VITROS® ß-hCG II
Wide dynamic range and equivalent results in serum and plasma minimize dilutions, provide flexibility and improve turnaround time.VITROS® Anti-HCV Assay
A version 3.0 fully automated, random-access diagnostic test for IgG antibody to hepatitis C virus. Provides improved sensitivity. Results in less than 60 minutes, available any time in any order.
VITROS® Electrolytes (Na+, Cl- and K+)
World-class Direct Ion Selective Electrodes (ISEs) with true results regardless of dilution, interferents or presence of abnormal proteins or lipids—all with lower overall costs.
VITROS® BuBc Assay
World-class Bilirubin results with direct BuBc measurement correlated to HPLC, high specificity and small sample volume, ideal for neonatal populations.
DAT & Toxicology
% Hemoglobin A1c
Troponin I ES
CA 125 IITM
TSH 3rd Gen
Total B-hCG II
HIV Ag/Ab Combo**
% Hemoglobin A1c
* Not approved or cleared for U.S. market
** In development
# HIV and Hepatitis co-developed with Novartis Vaccines and Diagnostics Inc.
PSA, CA125II, CA 15-3, CA 19-9 are tradmarks of Fujirebio Diagnostics, Inc.
Product availability subject to local regulatory requirements.
Note: Please consult your Ortho Clinical Diagnostics Sales Representative for the optimal VITROS® System solution to accommodate your specific menu needs. Product availability subject to local regulatory requirements.
1. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Eur Heart Journal. 2001;22:1527-1560.
2. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline update for the diagnosis and management of
chronic heart failure in the adult. Circulation. 2005;112:e154-e235.
3. Demers LM, Spencer CA. The National Academy of Clinical Biochemistry LaboratoryMedicine Practice Guidelines, Published Guidelines; Laboratory support for thediagnosis and monitoring of thyroid disease. 2002(13). http://www.aacc.org/sitecollectiondocuments/nacb/lmpg/thyroid/thyroidfullversionwithcover.pdf. Accessed on July 18, 2008.
4. Stockigt J. Chapter 6B: Clinical strategies in the testing of thyroid function. In: Thyroid Disease Manager. 2004.
http://www.thyroidmanager.org/Chapter6/6b-frame.htm. Accessed on July 18, 2008.
5. Spencer, CA; Thyroid Profiling for the 1990s; Free T4 Estimate or Sensitive TSH Measurement. J Clin Immunology. 1989;12:82-89.
6. Nicoloff JT, Spencer CA; Clinical Review 12; The use and misuse of the sensitive thyrotropin assays. J Clin Endocrinol Metab. 1990;71:553-558.
7. Christofides ND, Wilkinson E, Stoddart M, Ray DC, Beckett, GJ. Assessment of serum thyroxine binding capacity-dependent biases in free thyroxine assays. Clin Chem. 1999;45(4):520-5.
8. Sapin R, Schlienger JL, Gasser F, et al. Intermethod discordant free thyroxine measurements in bone marrow-transplanted patients. Clin Chem. 2000;46(3):418-22.